Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

On Saturday, Novo Nordisk (NVO) ended its plans to buy out Metsera (MTSR). Metsera has obesity drugs in the pipeline and is pre-revenue. Novo will let Pfizer (PFE) overpay for Metsera in a deal worth ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...